Medical therapy for Crohn's disease

Current Opinion in Gastroenterology

Volumn 14, Issue 4, 1998, Pages 306-311

  D'Haens, Geert ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; HEALING; HUMAN; INTESTINE FISTULA; LONG TERM CARE; MAINTENANCE THERAPY; REMISSION; REVIEW;

EID: 0031856835     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199807000-00006     Document Type: Review

References (52)

1. Rutgeerts P, Lofberg R, Malchow H, Larners C, Olaison G, Jewell D, Danielsson A, Goebell H, Østergaard Thompsen O, Lorenz Meyer H, et al.: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331:842-845.
2. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson LG, Persson T, and the Canadian IBD group: Oral budesonide for active Crohn's disease. N Engl J Med 1994. 331:836-841.
3. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG, and the global • Budesonide Study Group: Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997, 41:209-214. Interesting study demonstrating that the efficacy of budesonide is best when given as a single dose in the morning. It also confirms equal efficacy to prednisone for ileocolonic disease.
4. Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J, and the German Budesonide Study Group: Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. Hepatogastroenterology 1997, 44:445-451.
5. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, and the German/Austrian Budesonide Study Group: Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996, 8:905-910.
6. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Nylander I, and the International Budesonide-Mesalamine Study Group: Budesonide CIR is more effective than mesalazine in active Crohn's disease: a 16 week, international randomized, double-blind multicenter trial [abstract]. Gastroenterology 1997, 112:A1104.
7. Solomon MJ, McLeod RS, O'Connor BI, Steinhart AH, Greenberg GR, Cohen Z: Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993, 7:571-573.
8. Peppe'oorn MA: Is there a role for antibiotics as primary therapy in Crohn's disease? J Clin Gastroenterol 1993, 17:235-237.
9. Colombel JF, Lémann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY, and the GETAID: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease [abstract]. Gastroenterology 1997, 112:A951.
10. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ: An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995, 109:1808-1817.
11. Hanauer SB, Smith MB: Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993, 88:646-649.
12. Friedman S, Marion JF, Scherl E, Rubin P, Present DH: The treatment of choice for pyoderma gangrenosum complicating IBD: intravenous cyclosporin [abstract]. Gastroenterology 1997, 112:A975.
13. Sandborn WJ: Preliminary report on the use of oral tacrolimus (FK 506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997, 92:876-879.
14. Sands BE: Biologic therapy for inflammatory bowel disease. Inflammatory • Bowel Diseases 1997, 3:95-113. Excellent review of known and potential biologic therapies for inflammatory bowel disease. The authors refer to important basic work in animal models and cell and tissue cultures.
15. van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2). Gastroenterology 1995, 109:129-135.
16. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, for the Crohn's Disease cA2 Study Group: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997,337:1029-1035 Carefully designed international trial with a new biologic therapy. The exact place of this treatment modality in the therapeutic armamentarium for Crohn's disease needs to be further clarified.
17. van Deventer SJH, van Hogezand R, Present D, Hanauer S, Targan S, D'Haens G, DeWoody K, Braakman T, Schaible T, Rutgeerts P: Controlled study of anti-TNF-treatment for enterocutaneous fistulae complicating Crohn's disease [abstract]. Gut 1997, 41(suppl 3), A2.
18. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, • Long R, Forbes A, Kamm MA, Hawkey CJ: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997, 349:521-524. Interesting pilot trial with promising humanized anti-TNF antibodies. Comparison with other trials is somewhat difficult because of the unconventional definitions and statistical methods (see Sandborn, Gastroenterology 1997, 113:1042-1043).
19. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, • Long R, Forbes A, Kamm MA, Hawkey CJ: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997, 349:521-524. Interesting pilot trial with promising humanized anti-TNF antibodies. Comparison with other trials is somewhat difficult because of the unconventional definitions and statistical methods (see Sandborn, Gastroenterology 1997, 113:1042-1043).
20. Sandborn WJ: A controlled trial of anti-tumor necrosis factor α antibody for Crohn's disease: selected summary. Gastroenterology 1997, 113:1042-1043.
21. McGeehan GM, Bechere JD, Bast RC: Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994, 370:558-561.
22. Gearing AJ, Beckett P, Christodoulou M: Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994, 370:555-557.
23. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrich J: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988, 155:1230-1236.
24. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin induced cachectin/tumor factor synthesis at separate points in the signalling pathway. J Exp Med 1990, 172:391-394.
25. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S: • Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997, 40:470-474. Although this trial did not show benefit with oxpentifylline, the ideas behind it were definitely worth investigating. The trial illustrates the author's opinion that the inflammatory mechanisms in Crohn's disease are not exclusively TNF-α driven.
26. Schreiber S, Heinig T, Thiele H, Raedler A: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108:1434-1444.
27. van Deventer SJH, Elson CO, Fedorak RN, for the Crohn's Disease Study • Group: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997, 113:383-389. Complex but methodologically stringent pilot protocol for severe cases of Crohn's disease. Endoscopic and pharmacokinetic data clarify key aspects of this new therapeutic approach.
28. Fedorak RN, Gangl A, Elson CO, Gasche C, Rutgeerts P, D'Haens G, Schreiber S, Wild G, Hanauer SB, Sninsky CA, et al.: Safety, tolerance and activity of multiple doses of subcutaneous recombinant human interleukin-10 (rHuIL-10) in patients with mild to moderate active Crohn's disease [abstract]. Gut 1997, 41(suppl 3), A16.
29. Qiu BS, Pfeiffer CJ, Keith JC Jr: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996, 41:1625-1630.
30. Bank S, Sninsky C, Robinson M, Katz S, Singleton J, Miner P, Safdi M, Galandiuk S, Hanauer S, Varilek G, et al.: Safety and activity evaluation of rHIL-11 in subjects with active Crohn's disease [abstract]. Gastroenterology 1997, 112:A927.
31. Julius M, Maroun CR, Haughn L. Distinct roles for CD4 and CD8 as coreceptor in antigen receptor signaling. Immunol Today 1993, 14:177-187.
32. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJM, Tytgat GNJ, van Deventer SJH: CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 1997, 40:320-327.
33. Yacyshyn BR, Woloschuk B, Yacyshyn MB, Martini D, Doan K, Tami J, Bennett F, Kisner D, Shanahan W: Efficacy and safety to ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease [abstract]. Gastroenterology 1997, 112:A1123.
34. Messier A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, D'Albasio G, de Simone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a metaanalysis. Am J Gastroenterol 1994, 89:692-698.
35. Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:2116-2124.
36. Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997, 113:1465-1473.
37. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, •• Rossman R, Saibil F, Lariviere L, and the Canadian Mesalamine for Remission Study Group: A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. Gastroenterology 1997, 112:1069-1077. Interesting well-designed multicenter trial that is in fact negative. The statement of the authors that the trial is positive although statistical significance was not achieved is open to a lot of discussion.
38. Sahmoud T, Mary JY: Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Gut 1997, 40:284-285.
39. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soulé JC Gendre JP, Galmiche JP, et al., for GETAID: Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996, 110:688-693.
40. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, and the ECCDS VI Study Group. Prophylaxis of postoperative relapse in Crohn's disease with mesalazine (Pentasa) in comparison to placebo [abstract]. Gastroenterology 1997, 112:A1027.
41. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Cullen JB, et al.: Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995, 109:404-413.
42. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson LG, Persson T, and the Canadian IBD Group: Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996, 110:45-51.
43. Löfberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson Ȧ, Olaison G, Jewell D, Øtergaard Thomsen O, Lorenz-Meyer H, Goebell H, et al.: Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease: a placebo controlled one year study. Gut 1996, 39:82-86.
44. Feagan B, Greenberg GR, Löfberg R, Ferguson A, Persson T, International BUD Maintenance Investigators. Budesonide controlled ileal release prolonged remission in Crohn's disease: a pooled analysis. Gut 1997, 41(suppl 3), A17.
45. Lavy A: Triamcinolone improves outcome in Crohn's disease strictures. Dis Color Rectum 1997, 40:184-186.
46. Raedler A, Peters I, Screiber S. Treatment with azathioprine and budesonide prevents reoccurrence of ileocolonic stenosis after endoscopic dilatation in Crohn's disease [abstract]. Gastroenterology 1997, 112:A1067.
47. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980, 302:981-987.
48. O'Donoghue DP, Dawson AM, Powel-Tuck K, Bown RL, Lennard-Jones JE: Double-blind withdrawal trial of azathiopnne as maintenance treatment for Crohn's disease. Lancet 1978, ii:944-946.
49. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
50. D'Haens GR, Geboes K, Ponette E, Penninckx F, Rutgeerts P: Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997, 112:1475-1481.
51. Lémann M, Bouhnik Y, Kmieciak-Le Corguille M, Bonnett J, Coffin B, Marteau P, Bitoun A, Messing B, Jian R, Matuchansky C, et al.: Treatment of Crohn's disease with 6-mercaptopurine in patients intolerant to azathioprine [abstract]. Gastroenterology 1997, 112:A1025.
52. Rutgeerts P, D'Haens G, van Deventer SJH, Present DH, Mayer L, Hanauer SB, Braakman TAJ, De Woody KL, Schaible TF, Targan SR, and the Crohn's Disease cA2 Study Group: Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997, 112:A1078.